EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma

Brandon S Willis, Kevin Mongeon, Hannah Dry, India L Neveras, Nadezda Bryan, Meghana Pandya, Justine Roderick-Richardson, Wendan Xu, Li Yang, Alan Rosen, Corinne Reimer, Liliana Tuskova und 4 weitere

Leukemia · 2024

DOI: 10.1038/s41375-024-02401-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, 2024. Verfasst von Brandon S Willis und 15 weiteren Autor:innen. Beteiligte Einrichtung: Bioscience, Early Oncology, AstraZeneca, Boston, USA. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca providing funding to support experiments.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic potential of targeting PI3K/AKT/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-α/δ inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in part, due to treatment related toxicities. Clinically, AKT inhibitors exhibit a differentiated tolerability profile offering an alternative approach for treating patients with B-cell malignancies. To explore how AKT inhibition complements other potential therapeutics in the treatment of DLBCL patients, an in vitro combination screen was conducted across a panel of DLCBL cell lines. The AKT inhibitor, capivasertib, in combination with the BCL-2 inhibitor, venetoclax, produced notable therapeutic benefit in preclinical models of DLBCL. Capivasertib and venetoclax rapidly induced caspase and PARP cleavage in GCB-DLBCL PTEN wildtype cell lines and those harbouring PTEN mutations or reduced PTEN protein, driving prolonged tumour growth inhibition in DLBCL cell line and patient derived xenograft lymphoma models. The addition of the rituximab further deepened the durability of capivasertib and venetoclax responses in a RCHOP refractory DLBCL in vivo models. These findings provide preclinical evidence for the rational treatment combination of AKT and BCL-2 inhibitors using capivasertib and venetoclax respectively alongside anti-CD20 antibody supplementation for treatment of patients with DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseSulfonamidesBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2Antineoplastic Combined Chemotherapy ProtocolsPyrimidinesXenograft Model Antitumor AssaysHumansAnimalsMicePyrrolesCell Line, TumorApoptosisCell ProliferationRituximabMice, SCIDPTEN Phosphohydrolase

Substanzen

SulfonamidesBridged Bicyclo Compounds, HeterocyclicvenetoclaxProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2PyrimidinescapivasertibPyrrolesBCL2 protein, humanRituximab

Autor:innen und Institutionen

  • Bioscience, Early Oncology, AstraZeneca, Boston, USA.
  • Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
  • Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
  • Bioscience, Early Oncology, AstraZeneca, Cambridge, UK. simon.t.barry@astrazeneca.com.

ORCID-Profile: Georg Lenz, Simon T Barry

Förderung

  • AstraZeneca providing funding to support experiments

Zitieren

APA

Willis, B. S., Mongeon, K., Dry, H., Neveras, I. L., Bryan, N., Pandya, M., Roderick-Richardson, J., Xu, W., Yang, L., Rosen, A., Reimer, C., Tuskova, L., Klener, P., Mettetal, J. T., Lenz, G., & Barry, S. T. (2024). Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma. Leukemia. https://doi.org/10.1038/s41375-024-02401-9

Vancouver

Willis BS, Mongeon K, Dry H, Neveras IL, Bryan N, Pandya M, et al. Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma. Leukemia. 2024. doi:10.1038/s41375-024-02401-9

BibTeX
@article{Willis2024,
  author = {Willis, Brandon S and Mongeon, Kevin and Dry, Hannah and Neveras, India L and Bryan, Nadezda and Pandya, Meghana and Roderick-Richardson, Justine and Xu, Wendan and Yang, Li and Rosen, Alan and Reimer, Corinne and Tuskova, Liliana and Klener, Pavel and Mettetal, Jerome T and Lenz, Georg and Barry, Simon T},
  title = {Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma},
  journal = {Leukemia},
  year = {2024},
  doi = {10.1038/s41375-024-02401-9}
}
Kostenlos starten →